Autologous cancer vaccine extends survival in patients with newly diagnosed GBM

the ONA take:

Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed glioblastoma multiforme (GBM) improves survival. Patients in this single-arm, multi-institutional, open-label study who received the vaccine lived nearly twice as long as expected. Median survival was approximately 24 months, and 33% of patients remain alive at 2 years and continue to be followed for survival. Patients with GBM typically live for only 1 year after diagnosis. Prophage is an autologous cancer vaccine prepared from the patient’s own surgically resected tumor, an approach intended to create a tailor-made vaccine for the patient’s specific tumor. The investigators noted that Prophage seems to be more pronounced in patients with less expression of the checkpoint ligand PDL-1 on the white blood cells. This suggests that combining Prophage with checkpoint modulators such as PD-1 antagonists may make the vaccine even more effective in a greater percentage of patients with GBM.

Autologous cancer vaccine extends survival in patients with newly diagnosed GBM
Autologous cancer vaccine extends survival in patients with newly diagnosed GBM
Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected.
READ FULL ARTICLE From News Medical
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs